Cancer
Malignant Cervical Neoplasm
CI-CAN-00007992Explore in graph →
Top-level506 active trials4 approved drugs14 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00007992Explore in graph →
Clinical trials
1,994 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (181)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07702721 | Intraoperative Microscopic Assessment of Lymph Node Status in Gynecological Malignancies(IMAGINE) | not yet recruiting | — | 160 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
| 0 |
| Jul 14, 2026 |
| clinicaltrials |
| NCT07693452 | Metformin in Pseudomyxoma Peritonei Secondary to Appendiceal Mucinous Neoplasms | recruiting | Phase 2 | 15 | University of California, IrvineOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT03180294 | Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer | completed | Phase 2 | 230 | NRG OncologyOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07696169 | Disease Evolution and Risk Factors of AIDS-related Prevalent Cancers | not yet recruiting | — | 1,000 | Shenzhen Third People's HospitalOTHER | 0 | Jul 10, 2026 | clinicaltrials |
| NCT03587311 | Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 2 | Jul 8, 2026 | clinicaltrials |
| NCT02956031 | Screening Study for Cervical Pre-cancer and Cancer Prevention in South African Women.(DiaVACCS) | recruiting | — | 1,500 | University of PretoriaOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT05581121 | PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer(PAROLA) | recruiting | Phase 3 | 510 | Institut Claudius RegaudOTHER | 4 | Jul 7, 2026 | clinicaltrials |
| NCT06611540 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S03) | active not recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 7, 2026 | clinicaltrials |
| NCT06611553 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S02) | active not recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 2 | Jul 7, 2026 | clinicaltrials |
| NCT07676461 | Oral, Fecal and Intratumoral Microbiome Atlas in Colombian Patients With Advanced Solid Tumors Receiving First-Line Immunotherapy(ATLAS) | recruiting | — | 150 | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento AnguloOTHER | 1 | Jul 7, 2026 | clinicaltrials |
| NCT07406087 | Navigation Intervention for Adolescent and Young Adult Cancer Survivors | recruiting | N/A | 25 | Kaiser PermanenteOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT04214067 | Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer | active not recruiting | Phase 3 | 164 | National Cancer Institute (NCI)NIH | 2 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 | Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | active not recruiting | Phase 1 | 30 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07169734 | A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Alentis Therapeutics AGINDUSTRY | 8 | Jul 2, 2026 | clinicaltrials |
| NCT07436793 | Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial | recruiting | Phase 2 | 140 | New Mexico Cancer Research AllianceOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer | terminated | Phase 2 | 17 | University of Southern CaliforniaOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06315257 | A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer Patients | recruiting | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07678047 | Leveraging Project ECHO for Improved Cervical Cancer Screening in Ethiopia | enrolling by invitation | N/A | 60 | Albert Einstein College of MedicineOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06291311 | Non-Invasive Plasma Treatment for Cervical Infections: Targeting High- and Low-Risk HPV Variants | recruiting | — | 50 | University Hospital TuebingenOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05401175 | Hematopoietic Stem Cell-containing Autologous Blood Reinfusion for Bone Marrow Protection in Cervical Cancer Patients | recruiting | N/A | 40 | Chongqing University Cancer HospitalOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06747585 | A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Alentis Therapeutics AGINDUSTRY | 8 | Jun 29, 2026 | clinicaltrials |
| NCT07645625 | Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer(PROTECx) | recruiting | Phase 4 | 261 | University Medical Center GroningenOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673211 | Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer | not yet recruiting | — | 60 | Zhejiang Cancer HospitalOTHER | 0 | Jun 29, 2026 | clinicaltrials |
| NCT05082259 | ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab(ASTEROID) | active not recruiting | Phase 1 | 61 | Institute of Cancer Research, United KingdomOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668284 | COQ10 and Vitamin E for Off-Target Radiation Toxicity | not yet recruiting | Phase 1 / Phase 2 | 200 | University of NebraskaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06874985 | Effectiveness and Impact of the Lived Experience Cancer Awareness Campaign on Screening Participation | completed | N/A | 1,264 | International Agency for Research on CancerOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07667192 | Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer(Regynera-RT) | recruiting | — | 500 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07663006 | Breast and Cervical Cancer Stigma in Rwanda | not yet recruiting | N/A | 1,116 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03476681 | Study of NEO-201 in Solid Tumors Expansion Cohorts | active not recruiting | Phase 1 / Phase 2 | 121 | Precision Biologics, IncINDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04770090 | Research of Circulating Tumor Cells Released During Cervical Cancer Surgery(CTC-COL) | active not recruiting | N/A | 200 | University Hospital, MontpellierOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06147960 | Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer(EPIcol) | recruiting | — | 180 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06213571 | Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas | completed | N/A | 80 | Mayo ClinicOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT03833479 | TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation(ATOMICC) | active not recruiting | Phase 2 | 134 | Grupo Español de Investigación en Cáncer de OvarioOTHER | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07653503 | Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)(NEOLYNC) | recruiting | Phase 1 | 12 | University Medical Center GroningenOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07625943 | HYPOfractionated RadioTherapy in Cervical Cancer(HYPORT-CC) | recruiting | N/A | 396 | All India Institute of Medical SciencesOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07649174 | Cadonilimab Plus Chemotherapy in LACC: A Prospective, Multicenter, Randomized Phase II Trial | not yet recruiting | Phase 2 | 134 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04452526 | I Vaccinate: Testing Multi-Level Interventions to Improve HPV Vaccination(IVaccinate) | active not recruiting | N/A | 372 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06967961 | Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers(DP-PAN-CANCER) | recruiting | N/A | 450 | Institut Claudius RegaudOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07022470 | Phase II Trial Comparison of 3 vs 4 Fractions (BRACHY-FIT). | recruiting | Phase 2 | 41 | Stanford UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05283330 | Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors | recruiting | Phase 1 | 48 | Orano Med Theranostics, SASINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07218003 | A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 | enrolling by invitation | Phase 1 | 149 | Rondo TherapeuticsINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06825689 | Unidos Contra el VPH(Unidos) | recruiting | N/A | 735 | University of Texas at AustinOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06647992 | Effect of Nurse Navigation Program on Cervical Cancer Screening Behaviour of the Women Aged 30-65 | completed | N/A | 80 | TURKAN OZDASOTHER | 1 | Jun 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2026source: clinicaltrials